Merck & Company (MRK) has risen sharply, recording gains of 7.14% in the past 4 weeks. However, the stock has corrected -0.8% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 7.37% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
Company shares have received an average consensus rating of Hold for the current week The stock has recorded a twenty day Moving Average of 1.47% and the fifty day Moving Average is 5.46%. Merck & Co., Inc. is up 12.19% in the last three month period. Year-to-Date the stock performance stands at 21.01%.
Merck & Company (MRK) has been rated by 12 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $80 and the lowest price target forecast is $57. The average forecast of all the analysts is $65.67 and the expected standard deviation is $7.3.
Merck & Company (NYSE:MRK): stock turned positive on Friday. Though the stock opened at $62.48, the bulls momentum made the stock top out at $62.988 level for the day. The stock recorded a low of $62.18 and closed the trading day at $62.85, in the green by 0.85%. The total traded volume for the day was 7,793,815. The stock had closed at $62.32 in the previous days trading.
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.